IPH — Innate Pharma SA Cashflow Statement
0.000.00%
Last trade - 00:00- €112.44m
- €100.70m
- €2.79m
Annual cashflow statement for Innate Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.8 | -58.1 | -7.57 | -49.5 | -49.2 |
| Depreciation | |||||
| Non-Cash Items | -0.672 | 6.05 | 2.01 | 1.42 | 5.67 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.57 | -12.5 | -32.1 | 39.2 | -10.6 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -58.5 | -19.2 | -32.6 | -6.9 | -52.8 |
| Capital Expenditures | -1.33 | -1.12 | -2.35 | -0.391 | -0.14 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.414 | 3 | 23 | 9.59 | 7.43 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.917 | 1.88 | 20.6 | 9.2 | 7.29 |
| Financing Cash Flow Items | -0.312 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 26.8 | -1.83 | -1.97 | -6.01 | 6.07 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -33 | -19.5 | -13.6 | -4.21 | -38.3 |